Importance of tyrosine phosphorylation in angiotensin II type 1 receptor signaling

Hypertension
B SchiefferK E Bernstein

Abstract

Angiotensin II is the major effector peptide of the renin-angiotensin system. In addition to its vasoconstrictor activity, angiotensin II stimulates smooth muscle cell growth in arterial hypertension and in models of vascular injury. The angiotensin II type 1 receptor is a seven-transmembrane receptor and is responsible for virtually all the physiological actions of angiotensin II. This class of receptor signals in part through its association with heterotrimeric G proteins. A newly developed concept for guanine nucleotide protein-coupled receptors is the activation of intracellular second-messenger proteins via tyrosine phosphorylation. For instance, angiotensin II stimulates the rapid tyrosine phosphorylation and activation of phospholipase C-gamma1. Also, angiotensin II stimulates the tyrosine phosphorylation of Janus kinases. In this review, we discuss early signaling events induced by angiotensin II with an emphasis on tyrosine phosphorylation. Understanding the importance of tyrosine phosphorylation in the signaling pathways of the angiotensin II type 1 receptor may lead to new treatment modalities for cardiovascular disease.

References

Jul 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·P B Chock, E R Stadtman
Apr 30, 1990·Biochemical and Biophysical Research Communications·Y GranotR W Schrier
Feb 1, 1991·Trends in Pharmacological Sciences·P B TimmermansW F Herblin
May 1, 1985·Hypertension·R W AlexanderS E Rittenhouse
May 19, 1987·Biochemistry·H G DohlmanR J Lefkowitz
Jan 1, 1987·Annual Review of Biochemistry·M J Berridge
Jan 1, 1995·Annual Review of Biochemistry·C Schindler, J E Darnell
Mar 31, 1993·Biochemical and Biophysical Research Communications·F LiaoS G Rhee
Sep 13, 1993·Biochimica Et Biophysica Acta·B F Tate, S E Rittenhouse
Dec 1, 1994·European Heart Journal·C S Sweet, E J Rucinska
Jan 1, 1994·Annual Review of Cell Biology·P van der GeerR A Lindberg
Oct 3, 1994·FEBS Letters·B Rodríguez-Liñares, S P Watson
Jan 1, 1994·Advances in Pharmacology·K K GriendlingR W Alexander

❮ Previous
Next ❯

Citations

Apr 7, 1998·The American Journal of Medicine·E J Eichhorn
Feb 4, 1999·Regulatory Peptides·W G Thomas
Nov 5, 1997·General Pharmacology·M E Pueyo, J B Michel
Oct 13, 2000·British Journal of Pharmacology·H Y SohnU Pohl
Feb 9, 2002·British Journal of Pharmacology·Hiroshi Suenaga, Katsuo Kamata
Feb 1, 2000·Biochemical and Biophysical Research Communications·T SasaguriJ Ogata
Feb 13, 2001·Biochemical and Biophysical Research Communications·M LuchtefeldB Schieffer
Jun 10, 2000·Acta Physiologica Scandinavica·L SchiotzM J Mulvany
Jul 19, 2011·Progress in Neurobiology·Yannick Marc, Catherine Llorens-Cortes
Dec 3, 2014·Vascular Pharmacology·Angela Elena Vinturache, Francine Gabriel Smith
Dec 10, 1999·The American Journal of Cardiology·H Siragy
Oct 26, 1999·Journal of Receptor and Signal Transduction Research·B N BeckerR C Harris
Feb 21, 2018·The Korean Journal of Internal Medicine·Kwang Yong ShimSoon Koo Baik
Jun 7, 2018·Physiological Reviews·Steven J ForresterSatoru Eguchi
Jul 28, 2004·American Journal of Physiology. Heart and Circulatory Physiology·Ernesto L Schiffrin, Rhian M Touyz
Apr 6, 2000·American Journal of Physiology. Heart and Circulatory Physiology·T L PalloneZ Zhang
Feb 14, 2002·American Journal of Physiology. Gastrointestinal and Liver Physiology·Ya-Ping FanSatish Rattan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.